Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Duke University Janssen, LP |
---|---|
Information provided by: | Duke University |
ClinicalTrials.gov Identifier: | NCT00314613 |
Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Antipsychotic/Risperidone Consta |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label |
Official Title: | Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal |
Estimated Enrollment: | 30 |
Study Start Date: | April 2006 |
First episode patients have a greater potential for therapeutic response than multi-episode patients, and many of them also havea great desire to rejoin the workforce. Unfortunately, first episode patients become non-compliant or intermittently compliant with prescribed antipsychotic treatment at least as frequently as multi-episode patients. We believe that assured treatment with Risperal CONTSTA will provide first episode patients wiwth their best opporutnity for continued improvement in cognitive function beyond 3 months of treatment and that improvements in cognitive function will be associated with a greater likelihood of employment, real-world outcomes, such as independent living, as well as measures of brain function.
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: William H Wilson, PhD | 919-575-7360 | wilso066@mc.duke.edu |
United States, North Carolina | |
Duke University Medical Center | Recruiting |
Durham, North Carolina, United States, 27710 | |
Principal Investigator: William H Wilson, PhD | |
Sub-Investigator: Joseph P McEvoy, MD | |
John Umstead Hospital | Recruiting |
Butner, North Carolina, United States, 27509 |
Principal Investigator: | William H Wilson, PhD | Duke University |
Principal Investigator: | Joseph P McEvoy, MD | Duke University |
Study ID Numbers: | RIS-NAP-4007, 7858 |
Study First Received: | April 12, 2006 |
Last Updated: | April 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00314613 |
Health Authority: | United States: Institutional Review Board |
Schizophreniform; Schizophrenia; Schizoaffective Disorders |
Schizophrenia Dopamine Mental Disorders Risperidone |
Psychotic Disorders Serotonin Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |